

Reimbursement Policy

Serum Tumor Markers for Malignancies

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Circulating tumor biomarkers are substances detected in the blood, urine, or other body fluids that are either produced by a tumor itself or in response to its presence. These biomarkers can be used to help detect, diagnose, stage, and manage some types of cancer, because their amounts are typically elevated in individuals harboring a tumor.^{1,2} There are currently dozens of tumor markers in common use; this laboratory policy addresses tumor markers which may be measured in an individual’s serum.

Terms such as male and female are used when necessary to refer to sex assigned at birth.

The following management of serum tumor markers is built from recommendations from the National Comprehensive Cancer Network (NCCN) Biomarkers Compendium®, which contains information “designed to support decision making around the use of biomarker testing in patients with cancer. The NCCN Biomarkers Compendium® is updated in conjunction with the NCCN Guidelines on a continual basis.”³

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

Note: Except for where otherwise specified in the coverage criteria below, quarterly measurement of designated serum biomarkers is permitted for follow-up, monitoring, and/or surveillance

- 1) Measurement of the following serum biomarkers **MEETS COVERAGE CRITERIA** for the following indications:

Serum Biomarker	Indication
Alkaline phosphatase (ALP)	Bone neoplasms: workup
	Melanoma (uveal): workup

Reimbursement Policy

Serum Biomarker	Indication
Alpha fetoprotein (AFP)	<p>Systemic light chain amyloidosis: initial diagnostic workup</p> <hr/> <p>Hepatocellular carcinoma: screening; workup for confirmed HCC; surveillance (every 3-6 months for 2 years, then every 6 months)</p> <hr/> <p>Intrahepatic cholangiocarcinoma: workup for isolated intrahepatic mass</p> <hr/> <p>Occult primary: additional workup for localized adenocarcinoma or carcinoma not otherwise specified; liver, mediastinum, or retroperitoneal mass</p> <hr/> <p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p> <hr/> <p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors): monitoring/follow-up – Clear cell carcinoma of the ovary: monitoring/follow-up – Grade 1 endometrioid carcinoma: monitoring/follow-up – Mucinous neoplasms of the ovary: monitoring/follow-up – Low-grade serous carcinoma: monitoring/follow-up <p>Ovarian cancers:</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated) – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease) <hr/> <p>Testicular cancer – nonseminoma: workup; risk classification; surveillance (no more than every 2 months)</p> <hr/> <p>Testicular cancer - pure seminoma: initial diagnostic workup; post-diagnostic workup; risk classification; post-treatment surveillance (no more than every 2 months)</p> <hr/> <p>Thymomas and thymic carcinomas: initial evaluation, if appropriate</p>
Beta-2 microglobulin (B2M)	<p>B-cell lymphomas (diffuse large B-cell; follicular [grade 1-2]; HIV-related; lymphoblastic; mantle cell): workup</p> <hr/> <p>Castleman Disease: workup</p>

Reimbursement Policy

Serum Biomarker	Indication
	<p>Chronic lymphocytic leukemia/small lymphocytic lymphoma: workup; for prognostic and/or therapy determination</p> <hr/> <p>Multiple myeloma: initial diagnostic workup; follow-up/surveillance (as needed) for solitary plasmacytoma or solitary plasmacytoma with minimal marrow involvement</p> <hr/> <p>Systemic light chain amyloidosis: initial diagnostic workup</p> <hr/> <p>Waldenström macroglobulinemia / lymphoplasmacytic lymphoma: workup</p>
BNP or NT-proBNP	Multiple myeloma: initial diagnostic workup
Calcitonin (CALCA)	<p>Adenocarcinoma, and anaplastic/undifferentiated epithelial tumors: workup</p> <hr/> <p>Medullary carcinoma: additional workup; post-surgical evaluation; monitoring; surveillance (2-3 months postoperative, then every 6-12 months)</p> <hr/> <p>Multiple endocrine neoplasia, type 2: at diagnosis (clinical evaluation) for medullary thyroid cancer</p> <hr/> <p>Occult primary (unknown primary cancer): workup</p>
Cancer antigen 15-3 and 27.29 (CA 15-3 and 27.29)	<p>Breast cancer (invasive): monitoring metastatic disease</p> <hr/> <p>Occult primary: suspected metastatic malignancy: initial workup; assessing disease prognosis; monitoring/follow-up for response</p>
Cancer antigen 19-9 (CA 19-9)	<p>Ampullary adenocarcinoma: workup; surveillance (every 3-6 months for 2 years, then every 6-12 months for up to 5 years as clinically indicated) for resected ampullary cancer, stage I-III</p> <hr/> <p>Appendiceal adenocarcinoma: workup to establish baseline. Abnormal measurements should be trended</p> <hr/> <p>Extrahepatic cholangiocarcinoma: workup to establish baseline; monitoring</p> <hr/> <p>Gallbladder cancer: workup to establish baseline; monitoring; surveillance (as clinically indicated), post-resection</p> <hr/> <p>Intrahepatic cholangiocarcinoma: workup to establish baseline; monitoring</p> <hr/> <p>Occult primary: workup to establish baseline;</p> <hr/> <p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p>

Reimbursement Policy

Serum Biomarker	Indication
	<p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors): workup/monitoring/follow up – Clear cell carcinoma of the ovary: workup/monitoring/follow up – Grade 1 endometrioid carcinoma: workup/monitoring/follow up – Low-grade serous carcinoma: workup/monitoring/follow up – Mucinous neoplasms of the ovary: workup/monitoring/follow up <p>Ovarian cancers</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated) – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease) – Mucinous carcinoma of the ovary: additional workup (if not previously done) <hr/> <p>Pancreatic adenocarcinoma: workup to establish baseline; monitoring; post-operative, post-adjuvant treatment surveillance (every 3-6 months for 2 years, then every 6-12 months as clinically indicated)</p> <hr/> <p>Small bowel adenocarcinoma: workup to establish baseline; post-treatment surveillance (every 3-6 months for 2 years, then every 6 months for a total of 5 years); at metastasis or recurrence</p>
<p>Cancer antigen 125 (CA-125)</p>	<p>Appendiceal adenocarcinoma: workup to establish baseline</p> <hr/> <p>Endometrial carcinoma: additional workup; surveillance (if initially elevated)</p> <hr/> <p>Lynch syndrome: surveillance</p> <hr/> <p>Occult primary: initial evaluation/workup, additional workup for adenocarcinoma or carcinoma not otherwise specified, in those with a uterus and/or ovaries present</p> <hr/> <p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p>

Reimbursement Policy

Serum Biomarker	Indication
	<p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors): monitoring/follow-up – Clear cell carcinoma of the ovary: monitoring/follow-up – Mucinous neoplasms of the ovary: monitoring/follow-up – Grade 1 endometrioid carcinoma: monitoring/follow-up – Low-grade serous carcinoma: monitoring/follow-up <p>Ovarian cancers:</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated) – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 6 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease) <hr/> <p>Peritoneal mesothelioma: initial evaluation</p> <hr/> <p>Uterine neoplasms: initial workup, additional workup, surveillance</p>
<p>Carcinoembryonic antigen (CEA)</p>	<p>Appendiceal adenocarcinoma: workup to establish baseline; monitoring; post-treatment surveillance</p> <hr/> <p>Breast cancer (invasive): Monitoring metastatic disease</p> <hr/> <p>Colon cancer: workup to establish baseline; monitoring; surveillance (every 3-6 months for 2 years, then every 6 months for a total of 5 years)</p> <hr/> <p>Extrahepatic cholangiocarcinoma: workup to establish baseline; monitoring</p> <hr/> <p>Gallbladder cancer: workup to establish baseline; monitoring; surveillance; monitoring of adjuvant treatment (as clinically indicated), post-resection</p> <hr/> <p>Intrahepatic cholangiocarcinoma: workup to establish baseline; monitoring</p> <hr/> <p>Medullary carcinoma: diagnosis and additional workup; monitoring; post-surgical surveillance (2-3 months postoperative, then every 6-12 months)</p> <hr/> <p>Multiple endocrine neoplasia, type 2: at diagnosis (clinical evaluation) for medullary thyroid cancer</p> <hr/> <p>Occult primary (unknown primary cancer): workup for adenocarcinoma or carcinoma not otherwise specified</p>

Reimbursement Policy

Serum Biomarker	Indication
	<p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p> <hr/> <p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors): monitoring/follow-up – Clear cell carcinoma of the ovary: monitoring/follow-up – Grade 1 endometrioid carcinoma: monitoring/follow-up – Low-grade serous carcinoma: monitoring/follow-up – Mucinous neoplasms of the ovary: monitoring/follow-up <p>Ovarian cancers:</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated); post-adjuvant treatment – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease) – Mucinous carcinoma of the ovary: additional workup (if not previously done) <hr/> <p>Rectal cancer: workup to establish baseline; monitoring; surveillance (every 3-6 months for 2 years, then every 6 months for a total of 5 years)</p> <hr/> <p>Small bowel adenocarcinoma: workup to establish baseline; post-treatment surveillance (every 3-6 months for 2 years, then every 6 months for a total of 5 years)</p>
<p>Chorionic gonadotropin beta polypeptide (CGB3)</p>	<p>Gestational trophoblastic neoplasia: initial workup; during and post treatment (no more than weekly); follow-up/surveillance (no more than monthly for 12 months)</p> <hr/> <p>Occult primary: additional workup for localized adenocarcinoma or carcinoma not otherwise specified; individuals < 65 years of age with mediastinum or retroperitoneal mass</p> <hr/> <p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p> <hr/> <p>Ovarian cancers:</p>

Reimbursement Policy

Serum Biomarker	Indication
	<ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated) – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease) <hr/> <p>Testicular cancer – nonseminoma: workup; risk classification; surveillance (no more than every 2 months)</p> <hr/> <p>Testicular cancer – pure seminoma: workup; post-diagnostic workup; risk classification; post-treatment surveillance (no more than every 2 months)</p> <hr/> <p>Thymomas and thymic carcinomas: initial evaluation, if appropriate</p>
<p>Human epididymis protein 4 (HE4)</p>	<p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p> <hr/> <p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors): monitoring/follow-up – Clear cell carcinoma of the ovary: monitoring/follow-up – Grade 1 endometrioid carcinoma: monitoring/follow-up – Low-grade serous carcinoma: monitoring/follow-up – Mucinous neoplasms of the ovary: monitoring/follow-up <p>Ovarian cancers :</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated); post-adjvant treatment – Malignant germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease)
<p>Inhibin (INHA)</p>	<p>Occult primary (unknown primary cancer): additional workup for adenocarcinoma or carcinoma not otherwise specified</p>

Reimbursement Policy

Serum Biomarker	Indication
	<p>Ovarian cancer/fallopian tube cancer/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated)</p> <hr/> <p>Ovarian cancers (less common):</p> <ul style="list-style-type: none"> – Carcinosarcoma (malignant mixed mullerian tumors: monitoring/follow-up) – Clear cell carcinoma of the ovary: monitoring/follow-up – Grade 1 endometrioid carcinoma: monitoring/follow-up – Low-grade serous carcinoma: monitoring/follow-up – Mucinous neoplasms of the ovary: monitoring/follow-up <p>Ovarian cancers:</p> <ul style="list-style-type: none"> – Borderline epithelial tumors: monitoring/follow-up (every visit if initially elevated) – Malignant Germ cell tumors: surveillance (no more than every 2 months for the first 2 years, every 4 months in years 3-5, and then annually after year 5) – Malignant sex cord stromal tumors: surveillance if clinically indicated. If done, frequency based on stage (i.e., 6-12 months if early-stage, low-risk disease; 4-6 months if high-risk disease)
Serum free light chains	<p>Castleman disease: workup</p> <hr/> <p>Multiple myeloma: initial diagnostic workup; follow-up; surveillance (up to once per month)</p> <hr/> <p>Systemic light chain amyloidosis: initial diagnostic workup</p>
Troponin T	Systemic light chain amyloidosis: initial diagnostic workup
Tryptase	Systemic mastocytosis: initial diagnosis

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 2) For all other cancer indications not discussed above, use of the above biomarkers (alone or in a panel of serum tumor markers) **DOES NOT MEET COVERAGE CRITERIA.**
- 3) All other serum tumor markers not addressed above (alone or in a panel of serum tumor markers) **DO NOT MEET COVERAGE CRITERIA.**

Reimbursement Policy

- 4) For the screening and detection of cancer, analysis of proteomic patterns in serum **DOES NOT MEET COVERAGE CRITERIA.**

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, please visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

There are numerous FDA-approved tests for the assessment of serum tumor markers. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid Services (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81479	Unlisted molecular pathology procedure
81599	Unlisted multianalyte assay with algorithmic analysis
82105	Alpha-fetoprotein (AFP); serum
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)
82232	Beta-2 microglobulin
82308	Calcitonin
82378	Carcinoembryonic antigen (CEA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified

Reimbursement Policy

CPT	Code Description
83521	Immunoglobulin light chains (ie, kappa, lambda), free, each
83789	Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
83880	Natriuretic peptide
83950	Oncoprotein; HER-2/neu
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)
84075	Phosphatase, alkaline
84078	Phosphatase, alkaline; heat stable (total not included)
84080	Phosphatase, alkaline; isoenzymes
84484	Troponin, quantitative
84702	Gonadotropin, chorionic (hCG); quantitative
84703	Gonadotropin, chorionic (hCG); qualitative
84704	Gonadotropin, chorionic (hCG); free beta chain
84999	Unlisted chemistry procedure
86300	Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)
86301	Immunoassay for tumor antigen, quantitative; CA 19-9
86304	Immunoassay for tumor antigen, quantitative; CA 125
86305	Human epididymis protein 4 (HE4)
86316	Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549),
86336	Inhibin A
0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score Proprietary test: Overa™ (OVA1 Next Generation) Lab/manufacturer: Aspira Labs, Inc, Vermillion, Inc
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, CPTsma, algorithm reported as risk score for likelihood of malignancy Proprietary test: REVEAL Lung Nodule Characterization Lab/Manufacturer: MagArray, Inc
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas

Reimbursement Policy

CPT	Code Description
	Proprietary test: BeScreened™-CRC Lab/Manufacturer: Beacon Biomedical Inc
0404U	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression Proprietary test: Divitum®Tka Lab/Manufacturer: Biovica Inc
0558U	Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression Proprietary test: IGoCheck™ (Blood-Based Colorectal Cancer Test) Lab/Manufacturer: Milagen, Inc
0559U	Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression Proprietary test: Haystack MRDTM Baseline Lab/Manufacturer: Quest Diagnostics®
G0327	Colorectal cancer screening; blood-based biomarker

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

- Hottinger A, Hormigo A. Serum Biomarkers. *Encyclopedia of Cancer*. Springer Berlin Heidelberg; 2011. http://link.springer.com/referenceworkentry/10.1007/978-3-642-16483-5_5269
- NCI. Tumor Markers. <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet>
- NCCN. Biomarkers Compendium. <https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium>
- Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*. Nov 2011;9 Suppl 5:S1-32; quiz S33. doi:10.6004/jnccn.2011.0137
- Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice:

Reimbursement Policy

- Quality Requirements. *Clinical Chemistry*. 2008;54(8):e1.
doi:10.1373/clinchem.2007.094144
6. BeScreened. BeScreened. <https://bescreened.com/>
 7. Aspira Health. Ova1Plus®. <https://aspirawh.com/ovalplus/>
 8. ASPIRA. OvaWatch. <https://aspirawh.com/ovawatch/>
 9. Pinzani P, D'Argenio V, Del Re M, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. *Clin Chem Lab Med*. Jun 25 2021;59(7):1181-1200. doi:10.1515/cclm-2020-1685
 10. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. *Indian J Clin Biochem*. Jul 2014;29(3):269-78. doi:10.1007/s12291-013-0408-y
 11. Szulc P, Bauer DC, Dempster DW, Luckey M, Cauley JA. Osteoporosis. 2013;1doi:10.1016/B978-0-12-415853-5.00067-4
 12. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Systemic Light Chain Amyloidosis Version Version 2.2025. https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
 13. Thio Q, Karhade AV, Notman E, et al. Serum alkaline phosphatase is a prognostic marker in bone metastatic disease of the extremity. *J Orthop*. Nov-Dec 2020;22:346-351. doi:10.1016/j.jor.2020.08.008
 14. Schefer H, Mattmann S, Joss RA. Hereditary persistence of α -fetoprotein Case report and review of the literature. *Annals of Oncology*. 1998;9(6):667-672. doi:10.1023/A:1008243311122
 15. Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jul 10 2010;28(20):3388-404. doi:10.1200/jco.2009.26.4481
 16. Wu M, Liu H, Liu Z, Liu C, Zhang A, Li N. Analysis of serum alpha-fetoprotein (AFP) and AFP-L3 levels by protein microarray. *The Journal of international medical research*. Oct 2018;46(10):4297-4305. doi:10.1177/0300060518789304
 17. Singal AG, Llovet JM, Yarrowan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology*. May 22 2023;doi:10.1097/HEP.0000000000000466
 18. Santos Schraiber Ld, de Mattos AA, Zanotelli ML, et al. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. *Medicine*. Jan 2016;95(3):e2478. doi:10.1097/md.0000000000002478
 19. Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. *PloS one*. 2014;9(1):e87011. doi:10.1371/journal.pone.0087011
 20. Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. *Medicine*. Mar 2017;96(11):e5811. doi:10.1097/md.0000000000005811

Reimbursement Policy

21. Ryu T, Takami Y, Wada Y, et al. Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract*. Jun 2017;21(6):957-966. doi:10.1007/s11605-017-3394-1
22. Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. *Hepatology research : the official journal of the Japan Society of Hepatology*. Mar 2016;46(3):E130-5. doi:10.1111/hepr.12544
23. Berrebi A, Shvidel L, Arditti FD, Bassous L, Haran M, Shtalrid M. The Significance of Elevated Beta 2-Microglobulin (b2-m) in B-CLL: Evidence of in Vitro b2-m Secretion Following Activation of B-CLL Cells. *Blood*. 2009;114(22):4380.
24. Katou H, Kanno T, Hoshino M, et al. The role of disulfide bond in the amyloidogenic state of beta(2)-microglobulin studied by heteronuclear NMR. *Protein science : a publication of the Protein Society*. Sep 2002;11(9):2218-29. doi:10.1110/ps.0213202
25. Marcinko TM, Dong J, LeBlanc R, Daborowski KV, Vachet RW. Small molecule-mediated inhibition of β -2-microglobulin-based amyloid fibril formation. *The Journal of biological chemistry*. Jun 23 2017;292(25):10630-10638. doi:10.1074/jbc.M116.774083
26. Seo S, Hong JY, Yoon S, et al. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. *Oncotarget*. Nov 22 2016;7(47):76934-76943. doi:10.18632/oncotarget.12734
27. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. *Heart*. Jun 2006;92(6):843-9. doi:10.1136/hrt.2005.071233
28. Di Castelnuovo A, Veronesi G, Costanzo S, et al. NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke. *Stroke*. Mar 2019;50(3):610-617. doi:10.1161/STROKEAHA.118.023218
29. Venner CP. AL amyloidosis cardiac staging updated using BNP. *Blood*. Jan 17 2019;133(3):184-185. doi:10.1182/blood-2018-10-882159
30. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
31. Tuttle RM. Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging. Updated July 29, 2024. <https://www.uptodate.com/contents/medullary-thyroid-cancer-clinical-manifestations-diagnosis-and-staging>
32. Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid : official journal of the American Thyroid Association*. Jun 2015;25(6):567-610. doi:10.1089/thy.2014.0335
33. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and

Reimbursement Policy

- Differentiated Thyroid Cancer. *Thyroid : official journal of the American Thyroid Association*. Jan 2016;26(1):1-133. doi:10.1089/thy.2015.0020
34. Tormey WP, Byrne B, Hill AD, Sherlock M, Thompson CJ. Should serum calcitonin be routinely measured in patients presenting with thyroid nodule? *Minerva endocrinologica*. Dec 2017;42(4):306-310. doi:10.23736/s0391-1977.17.02566-4
 35. Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. *Archives of Biochemistry and Biophysics*. 2004/06/15/ 2004;426(2):122-131. doi:10.1016/j.abb.2004.04.008
 36. Isaksson S, Jönsson P, Monsef N, et al. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. *PloS one*. 2017;12(10):e0186284. doi:10.1371/journal.pone.0186284
 37. Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. *Cancer prevention research (Philadelphia, Pa)*. Sep 2011;4(9):1356-9. doi:10.1158/1940-6207.Ccrp-11-0378
 38. Kim NH, Lee MY, Park JH, et al. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. *Yonsei medical journal*. Sep 1 2017;58(5):918-924. doi:10.3349/ymj.2017.58.5.918
 39. Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. *BMC cancer*. Nov 9 2017;17(1):737. doi:10.1186/s12885-017-3738-y
 40. Lucarelli G, Ditonno P, Bettocchi C, et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. *Disease markers*. 2014;2014:689795. doi:10.1155/2014/689795
 41. Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. *Cancer Manag Res*. 2018;10:1313-1318. doi:10.2147/cmar.S155693
 42. Bind MK, Mishra RR, Kumar V, Misra V, Singh PA. Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder. *Indian J Pathol Microbiol*. Jan-Mar 2021;64(1):65-68.
 43. Li AJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. Updated October 31, 2024. <https://www.uptodate.com/contents/serum-biomarkers-for-evaluation-of-an-adnexal-mass-for-epithelial-carcinoma-of-the-ovary-fallopian-tube-or-peritoneum>
 44. Duffy MJ. Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful? *Clinical Chemistry*. 2001;47(4):624. doi:10.1093/clinchem/47.4.624
 45. Harvey RA. Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease. Updated June 23, 2023. <https://www.uptodate.com/contents/human-chorionic-gonadotropin-biochemistry-and-measurement-in-pregnancy-and-disease>
 46. Marcillac I, Troalen F, Bidart J-M, et al. Free Human Chorionic Gonadotropin β Subunit in Gonadal and Nongonadal Neoplasms. *Cancer Research*. 1992;52(14):3901.

Reimbursement Policy

47. Hotakainen K, Ljungberg B, Paju A, Rasmuson T, Alfthan H, Stenman UH. The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. *British journal of cancer*. Jan 21 2002;86(2):185-9. doi:10.1038/sj.bjc.6600050
48. Li J, Yin M, Song W, et al. B Subunit of Human Chorionic Gonadotropin Promotes Tumor Invasion and Predicts Poor Prognosis of Early-Stage Colorectal Cancer. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2018;45(1):237-249. doi:10.1159/000486770
49. Strosberg J. Diagnosis of carcinoid syndrome and tumor localization. Updated March 19, 2025. <https://www.uptodate.com/contents/diagnosis-of-the-carcinoid-syndrome-and-tumor-localization>
50. Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. *PloS one*. 2015;10(4):e0124884. doi:10.1371/journal.pone.0124884
51. Tian T, Gao J, Li N, et al. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. *PloS one*. 2016;11(5):e0154679. doi:10.1371/journal.pone.0154679
52. Walentowicz P, Krintus M, Sadlecki P, et al. Serum inhibin A and inhibin B levels in epithelial ovarian cancer patients. *PloS one*. 2014;9(3):e90575. doi:10.1371/journal.pone.0090575
53. Gershenson D. Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults. Updated July 8, 2024. <https://www.uptodate.com/contents/sex-cord-stromal-tumors-of-the-ovary-epidemiology-clinical-features-and-diagnosis-in-adults>
54. Farkkila A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B. *International journal of cancer*. Oct 1 2015;137(7):1661-71. doi:10.1002/ijc.29532
55. Kyrtsonis MC KE, Bartzis V, Pessah I, Nikolaou E, Karalis V, Maltezas D, Panayiotidis P, Harding S. Monoclonal Immunoglobulin. *Multiple Myeloma - A Quick Reflection on the Fast Progress*. 2012.
56. ACS. What Is Multiple Myeloma? <https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html>
57. Tosi P, Tomassetti S, Merli A, Polli V. Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. *Ther Adv Hematol*. Feb 2013;4(1):37-41. doi:10.1177/2040620712466863
58. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. *Clin Chem*. Sep 2002;48(9):1437-44.
59. ACS. What Is Waldenstrom Macroglobulinemia? <https://www.cancer.org/cancer/waldenstrom-macroglobulinemia/about/what-is-wm.html>
60. Cautha S, Gupta S, Hanif A, Moirangthem V, Jain K. Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression. *Eur J Case Rep Intern Med*. 2022;9(2):003106. doi:10.12890/2022_003106

Reimbursement Policy

61. Moreau AS LX, Manning R, Coiteux V, Darre S, Hatjiharisi E, Hunter Z, Jia X, Ngo H, O'Sullivan G, Santos D, Treon S, Facon T, Anderson K, Ghobrial I. Serum Free Light Chain in Waldenström Macroglobulinemia. 2006;doi:10.1182/blood.V108.11.2420.2420
62. Wu D, Lim MS, Jaffe ES. Pathology of Castleman Disease. *Hematol Oncol Clin North Am.* Feb 2018;32(1):37-52. doi:10.1016/j.hoc.2017.09.004
63. Oyaert M, Boone E, De Ceuninck L, et al. Clonal multicentric Castleman's disease with increased free Kappa light chains in a patient with systemic lupus erythematosus. *Ann Hematol.* Jul 2014;93(7):1255-7. doi:10.1007/s00277-013-1962-3
64. Stankowski-Drengler T, Gertz MA, Katzmann JA, et al. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *Am J Hematol.* Jun 2010;85(6):431-4. doi:10.1002/ajh.21707
65. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. *Blood.* Jun 27 2013;121(26):5124-30. doi:10.1182/blood-2013-01-453001
66. Dispenzieri A. Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis. Updated February 19, 2025. <https://www.uptodate.com/contents/clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis>
67. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood.* Dec 9 2010;116(24):5126-9. doi:10.1182/blood-2010-06-290668
68. Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. *Ann Clin Biochem.* Sep 2014;51(Pt 5):528-42. doi:10.1177/0004563213518758
69. Akar H, Seldin DC, Magnani B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. *Amyloid.* Dec 2005;12(4):210-5. doi:10.1080/13506120500352339
70. Chaulin AM. Biology of Cardiac Troponins: Emphasis on Metabolism. *Biology (Basel).* Mar 11 2022;11(3)doi:10.3390/biology11030429
71. Sharma S, Jackson PG, Makan J. Cardiac troponins. *J Clin Pathol.* Oct 2004;57(10):1025-6. doi:10.1136/jcp.2003.015420
72. Perfetto F, Bergesio F, Emdin M, Cappelli F. Troponins in cardiac amyloidosis: multipurpose markers. *Nat Rev Cardiol.* Mar 2014;11(3):179. doi:10.1038/nrcardio.2013.129-c1
73. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. *Blood.* Jun 17 2010;115(24):4981-90. doi:10.1182/blood-2010-01-257287
74. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. *Anaesthesia.* Jul 2004;59(7):695-703. doi:10.1111/j.1365-2044.2004.03757.x
75. Leru PM. Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice. *Cureus.* Feb 2022;14(2):e22177. doi:10.7759/cureus.22177

Reimbursement Policy

76. AAAAI. Systemic Mastocytosis. <https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis>
77. Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. *Breast cancer research and treatment*. 1998;52(1-3):99-111. doi:10.1007/978-1-4615-5195-9_15
78. Malmstrom P, Bendahl PO, Boiesen P, Brunner N, Idvall I, Ferno M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Apr 01 2001;19(7):2010-9. doi:10.1200/jco.2001.19.7.2010
79. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. *Cancer Res*. Feb 01 2000;60(3):636-43.
80. Chappuis PO, Dieterich B, Sciretta V, et al. Functional evaluation of plasmin formation in primary breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. May 15 2001;19(10):2731-8. doi:10.1200/jco.2001.19.10.2731
81. Foukakis T, Bergh J. Prognostic and predictive factors in early, nonmetastatic breast cancer - UpToDate. Updated March 17, 2025. <https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-early-non-metastatic-breast-cancer>
82. Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Apr 01 2016;34(10):1134-50. doi:10.1200/jco.2015.65.2289
83. Raby B. Personalized medicine. Updated September 6, 2023. <https://www.uptodate.com/contents/personalized-medicine>
84. Chen Y, Xie Y, Xu L, et al. Protein content and functional characteristics of serum-purified exosomes from patients with colorectal cancer revealed by quantitative proteomics. *International journal of cancer*. 2017/02/15 2017;140(4):900-913. doi:10.1002/ijc.30496
85. Qin J, Yang Q, Ye H, et al. Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer. *J Oncol*. 2020;2020:9430737. doi:10.1155/2020/9430737
86. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer Version 2.2025. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
87. Van Poznak C, Somerfield MR, Bast RC, et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Aug 20 2015;33(24):2695-704. doi:10.1200/jco.2015.61.1459
88. Stoffel EM, McKernin SE, Brand R, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. *Journal of Clinical Oncology*. 2019/01/10 2018;37(2):153-164. doi:10.1200/JCO.18.01489

Reimbursement Policy

89. Kindler HL, Ismaila N, Armato SG, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*. 2018/05/01 2018;36(13):1343-1373. doi:10.1200/JCO.2017.76.6394
90. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. *Clin Chem*. Jun 2010;56(6):e1-48. doi:10.1373/clinchem.2009.133124
91. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. *Clin Chem*. Dec 2008;54(12):e11-79. doi:10.1373/clinchem.2008.105601
92. ADLM. Human Chorionic Gonadotropin (hCG). <https://myadlm.org/cln/articles/2021/april/using-human-chorionic-gonadotropin-as-a-tumor-marker>
93. ADLM. Serum Free Light Chains: Optimal Testing Recommendations. <https://www.myadlm.org/advocacy-and-outreach/optimal-testing-guide-to-lab-test-utilization/g-s/serum-free-light-chains>
94. NANETS. NANETS 2024 Compendium. 2025. https://nanets.net/images/NANETS_2024_Symposium_Guidelines_Compendium.pdf
95. Bowlus CL, Arrive L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology*. Feb 1 2023;77(2):659-702. doi:10.1002/hep.32771
96. ATA. Revised ATA Management Guidelines for MTC. <https://www.thyroid.org/wp-content/uploads/2017/03/revised-ata-management-guidelines-for-MTC.pdf>

VI. Revision History

Revision Date	Summary of Changes
06/04/2025	<p>Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Based on guidance from the National Comprehensive Cancer Network’s Biomarker’s Compendium, the following coverage additions and removals were made:</p> <p>Adjusted terminology from 'serum tumor markers' in Note and CC1 to broaden definition as some serum-related markers are more accurately described as biomarkers rather than serum tumor markers. Changed title in table from “Serum Tumor Markers” to “Serum Biomarkers.”</p> <p>Alkaline phosphatase: For ALP, removed “during treatment, surveillance” from indications for ALP testing for bone neoplasms. Added “Melanoma (uveal)” as an indication for workup for ALP. Removed the words “post-</p>

Reimbursement Policy

	<p>diagnostic” from “Testicular cancer – nonseminoma” to clarify that workup can occur before or after diagnosis.</p> <p>Beta-2 microglobulin: For Beta-2 microglobulin, removed “Castleman disease” from B-cell lymphoma title and created a new row which identifies the indication for Castleman disease as “workup” with B2M measurement.</p> <p>Chorionic gonadotropin beta polypeptide expression (CGB3): Changed the title of “Beta-human chorionic gonadotropin (beta-HCG)” to “Chorionic gonadotropin beta polypeptide (CGB3).” Changed the words “testes presenting with” to “mediastinum or” under “Occult primary” designation.</p> <p>BNP or NT-proBNP: For BNP or NT-proBNP, removed “systemic light chain amyloidosis” and indication for “initial diagnostic workup” from BNP or NT-proBNP section (this was moved to a separate section with Troponin T.).</p> <p>Cancer antigen 19-9 (CA 19-9): For cancer antigen 19-9 (CA 19-9), removed “assessing disease prognosis; monitoring/follow-up for response” from Occult primary indications. In “Ovarian cancers (less common)” merged ovarian cancer sections. Added “monitoring/follow up” as indications to “Carcinosarcoma, Clear cell carcinoma of the ovary, Grade 1 endometrial carcinoma, low-grade serous carcinoma,” and “mucinous neoplasms of the ovary.”</p> <p>Cancer antigen 125 (CA-125): For cancer antigen 125 (CA-125), added “initial evaluation/workup” to indications for Occult primary. Added “additional workup/surveillance” indications to uterine neoplasms.</p> <p>Carcinoembryonic antigen (CEA): For Carcinoembryonic antigen (CEA), added Occult primary and indication for “workup for adenocarcinoma or carcinoma not otherwise specified.”</p> <p>Human epididymis protein 4 (HE4): For Human epididymis protein 4, added new section to the table. Added “Ovarian cancer/fallopian tube cancer/primary peritoneal cancer” with indications for “initial workup during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated).” Added “Ovarian cancers (less common) and indications for various cancers under this designation for “monitoring/follow-up.” Added “Ovarian cancers” and additional indications for “borderline epithelial tumors, malignant germ cell tumors, malignant sex cord stromal tumors.”</p> <p>Inhibin (INHA): For Inhibin (INHA), removed “adrenocortical carcinoma” and indication for “workup” from Inhibin (INHA) section. Added “Occult primary</p>
--	---

Reimbursement Policy

	<p>(unknown primary cancer)” with indications for “additional workup for adenocarcinoma or carcinoma not otherwise specified.”</p> <p>Lactate dehydrogenase (LDH): Removed the entire section on Lactate dehydrogenase (LDH) as LDH is a broad marker beyond serum tumor biomarker designation.</p> <p>Serum free light chains: Under Serum free light chains added “Castleman disease:” with indications for “workup” and added “follow-up” to Multiple myeloma as an indication.</p> <p>Added CPT code 0558U, 0559U (effective date 7/1/2025)</p> <p>Removed CPT code 83615</p>
--	---